Stem Cells Industry Data Book - Human Embryonic Stem Cells, Induced Pluripotent Stem Cells Production, Mesenchymal Stem Cells and Cancer Stem Cells Market Size, Share, Trends Report

Stem Cells Industry Data Book - Human Embryonic Stem Cells, Induced Pluripotent Stem Cells Production, Mesenchymal Stem Cells and Cancer Stem Cells Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030

  • Published Date: Feb, 2023
  • Report ID: sector-report-00158
  • Format: Electronic (PDF)
  • Number of Pages: 250

Chapter 1. Methodology and Scope

  •       1.1. Market Segmentation
  •          1.1.1. Estimates And Forecast Timeline
  •       1.2. Research Methodology
  •       1.3. Information Procurement
  •          1.3.1. Purchased Database
  •          1.3.2. GVR’s Internal Database
  •          1.3.3. Secondary Sources
  •          1.3.4. Primary Research
  •          1.3.5. Details Of Primary Research
  •       1.4. Information Or Data Analysis
  •          1.4.1. Data Analysis Models
  •       1.5. Market Formulation & Validation
  •       1.6. Model Details
  •          1.6.1. Commodity Flow Analysis
  •          1.6.2. Approach 1: Commodity Flow Approach
  •          1.6.3. Approach 2: Country-wise market estimation using bottom-up approach
  •       1.7. Global Market: CAGR Calculation
  •       1.8. Research Assumptions
  •       1.9. List of Secondary Sources
  •          1.9.1. List of Primary Sources
  •       1.10. Objectives
  •          1.10.1. Objective 1
  •          1.10.2. Objective 2
  •       1.11. List Of Abbreviations

Chapter 2. Executive Summary

  •       2.1. Market Snapshot
  •       2.2. Segment Snapshot
  •       2.3. Competitive Landscape Snapshot

Chapter 3. Global Stem Cells Industry Variables, Trends, & Scope

  •       3.1. Market Segmentation and Scope
  •       3.2. Stem Cells Industry Lineage Outlook
  •          3.2.1. Parent Market Outlook
  •          3.2.2. Related/Ancillary Market Outlook
  •       3.3. Market Trends and Outlook
  •       3.4. Market Dynamics
  •          3.4.1. Ongoing Developments In Regenerative Medicine
  •          3.4.2. Rising Funds For Accelerating Stem Cell Research
  •          3.4.3. Growing Demand For Stem Cell Banking
  •          3.4.4. Increasing Prevalence Of Genetic Disorders
  •          3.4.5. R&D in toxicology testing
  •          3.4.6. Technological advancements for the production of embryonic stem cells through alternative methods
  •          3.4.7. Increase In Demand For Ipscs Over Embryonic Stem Cells (Escs)
  •          3.4.8. Rise In The Integration Of Automation In Ipsc Production
  •          3.4.9. Expanding Exploitation Of Ipscs In Research
  •          3.4.10. Expanding Pipeline And Clinical Studies Of Mesenchymal Stem Cell Based Products
  •          3.4.11. Emerging Applications of MSCs
  •          3.4.12. Rising Market Competition Among Key Players
  •          3.4.13. Increasing stem cell-based clinical trials
  •          3.4.14. Robust pipeline of anti-CSCs therapeutics
  •          3.4.15. Rising new cases of cancer
  •       3.5. Market Restraint Analysis
  •          3.5.1. Ethical Concern Related To Stem Cell Research
  •          3.5.2. Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
  •          3.5.3. Clinical issues pertaining to development & implementation of stem cell therapy
  •                3.5.3.1. Manufacturing issues
  •                3.5.3.2. Genetic instability
  •                3.5.3.3. Stem cell culture condition
  •                3.5.3.4. Stem cell distribution after transplant
  •                3.5.3.5. Immunological rejection
  •          3.5.4. Lack Of Standardized & Regulated Delivery of Stem Cell Therapy
  •          3.5.5. Scalable Manufacturing Of Ipscs
  •       3.6. Penetration and Growth Prospect Mapping 2022
  •       3.7. Major Deals and Strategic Alliances Analysis
  •          3.7.1. New product launch
  •          3.7.2. Mergers and acquisitions
  •          3.7.3. Expansion
  •          3.7.4. Partnerships
  •          3.7.5. Marketing & promotions
  •          3.7.6. Market entry strategies
  •       3.8. Stem Cells Market Analysis Tools
  •          3.8.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  •          3.8.2. Porter’s Five Forces Analysis
  •       3.9. Human Embryonic Stem Cells Market Analysis Tools
  •          3.9.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  •          3.9.2. Porter’s Five Forces Analysis
  •       3.10. Induced Pluripotent Stem Cells Production Market Analysis Tools
  •          3.10.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  •          3.10.2. Porter’s Five Forces Analysis
  •       3.11. Mesenchymal Stem Cells Market Analysis Tools
  •          3.11.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  •          3.11.2. Porter’s Five Forces Analysis
  •       3.12. Cancer Stem Cells Market Analysis Tools
  •          3.12.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  •          3.12.2. Porter’s Five Forces Analysis
  •       3.13. Stem Cells Market Analysis Tools
  •          3.13.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  •          3.13.2. Porter’s Five Forces Analysis
  •       3.14. COVID-19 Impact Analysis

Chapter 4. Stem Cells Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

  •       4.1. Global Stem Cells Market: Product Movement Analysis
  •       4.2. Adult Stem Cells (ASCs)
  •          4.2.1. Adult Stem Cells (Ascs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          4.2.2. Hematopoietic Stem Cells (Blood Stem Cells)
  •                4.2.2.1. Hematopoietic stem cells (blood stem cells) market estimates and forecasts, 2018 - 2030 (USD Million)
  •          4.2.3. Mesenchymal Stem Cells
  •                4.2.3.1. Mesenchymal stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
  •          4.2.4. Neural Stem Cells
  •                4.2.4.1. Neural stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
  •          4.2.5. Epithelial/Skin Stem Cells
  •                4.2.5.1. Epithelial/Skin stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
  •          4.2.6. Other Adult Stem Cells
  •                4.2.6.1. Other adult stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
  •       4.3. Human Embryonic Stem Cells
  •          4.3.1. Human Embryonic Stem Cells Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       4.4. Induced Pluripotent Stem Cells
  •          4.4.1. Induced Pluripotent Stem Cells Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       4.5. Very Small Embryonic Like Stem Cells
  •          4.5.1. Very Small Embryonic Like Stem Cells Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Stem Cells Market- Segment Analysis, by Application, 2018 - 2030 (USD Million)

  •       5.1. Stem Cells Market: Application Movement Analysis
  •       5.2. Regenerative Medicine
  •          5.2.1. Regenerative Medicine Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          5.2.2. Neurology
  •                5.2.2.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.3. Orthopedics
  •                5.2.3.1. Orthopedics market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.4. Oncology
  •                5.2.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.5. Hematology
  •                5.2.5.1. Hematology market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.6. Cardiovascular and Myocardial Infraction
  •                5.2.6.1. Cardiovascular and myocardial infraction market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.7. Injuries
  •                5.2.7.1. Injuries market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.8. Diabetes
  •                5.2.8.1. Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.9. Liver Disorder
  •                5.2.9.1. Liver Disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.10. Incontinence
  •                5.2.10.1. Incontinence market estimates and forecasts, 2018 - 2030 (USD Million)
  •          5.2.11. Others
  •                5.2.11.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  •       5.3. Drug Discovery and Development
  •          5.3.1. Drug Discovery And Development Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Stem Cells Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)

  •       6.1. Global Stem Cells Market: Technology Movement Analysis
  •       6.2. Cell Acquisition
  •          6.2.1. Cell Acquisition Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          6.2.2. Bone Marrow Harvest
  •                6.2.2.1. Bone Marrow Harvest market estimates and forecasts, 2018 - 2030 (USD Million)
  •          6.2.3. Umbilical Blood Cord
  •                6.2.3.1. Umbilical Blood Cord market estimates and forecasts, 2018 - 2030 (USD Million)
  •                6.2.3.2. Apheresis
  • 6.2.3.2.1. Apheresis market estimates and forecasts, 2018 - 2030 (USD Million)
  •       6.3. Cell Production
  •          6.3.1. Cell Production Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          6.3.2. Therapeutic Cloning
  •                6.3.2.1. Therapeutic Cloning market estimates and forecasts, 2018 - 2030 (USD Million)
  •          6.3.3. In Vitro Fertilization
  •                6.3.3.1. In Vitro Fertilization market estimates and forecasts, 2018 - 2030 (USD Million)
  •          6.3.4. Cell Culture
  •                6.3.4.1. Cell Culture market estimates and forecasts, 2018 - 2030 (USD Million)
  •          6.3.5. Isolation
  •                6.3.5.1. Isolation market estimates and forecasts, 2018 - 2030 (USD Million)
  •       6.4. Cryopreservation
  •          6.4.1. Cryopreservation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       6.5. Expansion And Sub-Culture
  •          6.5.1. Expansion And Sub-Culture Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Stem Cells Market - Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  •       7.1. Global Stem Cells Market: Therapy Movement Analysis
  •       7.2. Autologous
  •          7.2.1. Autologous Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       7.3. Allogenic
  •          7.3.1. Allogenic Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Stem Cells Market - Segment Analysis, By End-User, 2018 - 2030 (USD Million)

  •       8.1. Global Stem Cells Market: End-User Movement Analysis
  •       8.2. Pharmaceutical And Biotechnology Companies
  •          8.2.1. Pharmaceutical And Biotechnology Companies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       8.3. Hospitals & Cell Banks
  •          8.3.1. Hospitals & Cell Banks Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       8.4. Academic & Research Institutes
  •          8.4.1. Academic & Research Institutes Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis

  •       9.1. Global Human Embryonic Stem Cells Market: Application Movement Analysis
  •       9.2. Regenerative Medicine
  •          9.2.1. Global regenerative medicine market, 2018 - 2030 (USD Million)
  •       9.3. Stem Cell Biology Research
  •          9.3.1. Global stem cell biology research market, 2018 - 2030 (USD Million)
  •       9.4. Tissue Engineering
  •          9.4.1. Global tissue engineering market, 2018 - 2030 (USD Million)
  •       9.5. Toxicology Testing
  •          9.5.1. Global toxicology testing market, 2018 - 2030 (USD Million)

Chapter 10. Induced Pluripotent Stem Cells (Ipscs) Production Market: Process Estimates & Trend Analysis

  •       10.1. Induced Pluripotent Stem Cells (Ipsc) Production Market: Process Movement Analysis
  •       10.2. Manual Ipsc Production Process
  •          10.2.1. Manual Ipsc Production Process market, 2018 - 2030 (USD Million)
  •       10.3. Automated Ipsc Production Process
  •          10.3.1. Automated Ipsc Production Process market, 2018 - 2030 (USD Million)

Chapter 11. Induced Pluripotent Stem Cells (Ipscs) Production Market: Workflow Estimates & Trend Analysis

  •       11.1. Induced Pluripotent Stem Cells (Ipsc) Production Market: Workflow Movement Analysis
  •       11.2. Reprogramming
  •          11.2.1. Reprograming market, 2018 - 2030 (USD Million)
  •       11.3. Cell Culture
  •          11.3.1. Cells Culture market, 2018 - 2030 (USD Million)
  •       11.4. Cell Characterization/Analysis
  •          11.4.1. Cells Characterization/Analysis market, 2018 - 2030 (USD Million)
  •       11.5. Engineering
  •          11.5.1. Engineering market, 2018 - 2030 (USD Million)
  •       11.6. Other
  •          11.6.1. Other Workflows market, 2018 - 2030 (USD Million)

Chapter 12. Induced Pluripotent Stem Cells (Ipscs) Production Market: Product Estimates & Trend Analysis

  •       12.1. Induced Pluripotent Stem Cells (Ipsc) Production Market: Product Movement Analysis
  •       12.2. Instruments/Devices
  •          12.2.1. Instruments/Devices market, 2018 - 2030 (USD Million)
  •       12.3. Automated Platforms
  •          12.3.1. Automated Platforms market, 2018 - 2030 (USD Million)
  •       12.4. Consumables & Kits
  •          12.4.1. Consumables & Kits market, 2018 - 2030 (USD Million)
  •          12.4.2. Media
  •                12.4.2.1. Media market, 2018 - 2030 (USD Million)
  •          12.4.3. Kits
  •                12.4.3.1. Kits market, 2018 - 2030 (USD Million)
  •          12.4.4. Others
  •                12.4.4.1. Other market, 2018 - 2030 (USD Million)
  •       12.5. Services
  •          12.5.1. Services market, 2018 - 2030 (USD Million)

Chapter 13. Induced Pluripotent Stem Cells (Ipscs) Production Market: Application Estimates & Trend Analysis

  •       13.1. Induced Pluripotent Stem Cells (Ipscs) Production Market: Application Movement Analysis
  •       13.2. Drug Development And Discovery
  •          13.2.1. Drug Development And Discovery market, 2018- 2030 (USD Million)
  •       13.3. Regenerative Medicine
  •          13.3.1. Regenerative Medicine market, 2018- 2030 (USD Million)
  •       13.4. Toxicology Studies
  •          13.4.1. Toxicology Studies market, 2018- 2030 (USD Million)

Chapter 14. Induced Pluripotent Stem Cells (Ipscs) Production Market: End-User Estimates & Trend Analysis

  •       14.1. Induced Pluripotent Stem Cells (Ipscs) Production Market: End-User Movement Analysis
  •       14.2. Research And Academic Institutes
  •          14.2.1. Research And Academic Institutes market, 2018- 2030 (USD Million)
  •       14.3. Biotechnology & Pharmaceutical Companies
  •          14.3.1. Biotechnology & Pharmaceutical Companies market, 2018- 2030 (USD Million)
  •       14.4. Hospitals & Clinics
  •          14.4.1. Hospitals & Clinics market, 2018- 2030 (USD Million)

Chapter 15. Mesenchymal Stem Cells (MSCs) Market: Product & Services Estimates & Trend Analysis

  •       15.1. Mesenchymal Stem Cells Market: Product & Services Movement Analysis
  •       15.2. By Workflow
  •          15.2.1. Cell Sourcing And Isolation
  •                15.2.1.1. Cell Sourcing And Isolation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          15.2.2. Culture & Cryopreservation
  •                15.2.2.1. Culture & Cryopreservation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          15.2.3. Differentiation
  •                15.2.3.1. Differentiation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          15.2.4. Characterization
  •                15.2.4.1. Characterization Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       15.3. By Product
  •          15.3.1. Cells & Cell Lines
  •                15.3.1.1. Cells And Cell Lines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          15.3.2. Kits, Media & Reagents
  •                15.3.2.1. Kits, Media & Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •          15.3.3. Others
  •                15.3.3.1. Others Mesenchymal Stem Cell Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       15.4. Services
  •          15.4.1. Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 16. Mesenchymal Stem Cells (MSCs) Market: Type Estimates & Trend Analysis

  •       16.1. Mesenchymal Stem Cells Market: Type Movement Analysis
  •       16.2. Autologous
  •          16.2.1. Autologous MSCs Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       16.3. Allogeneic
  •          16.3.1. Allogeneic MSCs Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 17. Mesenchymal Stem Cells (MSCs) Market: Source Of Isolation Estimates & Trend Analysis

  •       17.1. Mesenchymal Stem Cells Market: Source Of Isolation Movement Analysis
  •       17.2. Bone Marrow
  •          17.2.1. Bone Marrow Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)
  •       17.3. Cord Blood
  •          17.3.1. Cord Blood Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)
  •       17.4. Peripheral Blood
  •          17.4.1. Peripheral Blood Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)
  •       17.5. Fallopian Tube
  •          17.5.1. Fallopian Tube Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)
  •       17.6. Fetal Liver
  •          17.6.1. Fetal Liver Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)
  •       17.7. Lung
  •          17.7.1. Lung Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)
  •       17.8. Adipose Tissues
  •          17.8.1. Adipose Tissue Derived MSCs Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 18. Mesenchymal Stem Cells (MSCs) Market: Indication Estimates & Trend Analysis

  •       18.1. Mesenchymal Stem Cells Market: Indication Movement Analysis
  •       18.2. Bone & Cartilage Repair
  •          18.2.1. Bone & Cartilage Repair Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       18.3. Cardiovascular Disease
  •          18.3.1. Cardiovascular Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       18.4. Inflammatory And Immunological Disease
  •          18.4.1. Inflammatory And Immunological Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       18.5. Liver Diseases
  •          18.5.1. Liver Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       18.6. Cancer
  •          18.6.1. Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       18.7. GvHD
  •          18.7.1. GvHD Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       18.8. Others
  •          18.8.1. Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 19. Mesenchymal Stem Cells (MSCs) Market: Application Estimates & Trend Analysis

  •       19.1. Mesenchymal Stem Cells Market: Application Movement Analysis
  •       19.2. Disease Modeling
  •          19.2.1. Disease Modeling Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       19.3. Drug Development & Discovery
  •          19.3.1. Drug Development & Discovery Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       19.4. Stem Cell Banking
  •          19.4.1. Stem Cell Banking Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       19.5. Tissue Engineering
  •          19.5.1. Tissue Engineering Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       19.6. Toxicology Studies
  •          19.6.1. Toxicology Studies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  •       19.7. Others
  •          19.7.1. Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 20. Cancer Stem Cells Market: Mode of Action Estimates & Trend Analysis

  •       20.1. Global Cancer stem cells market: Mode of Action Movement Analysis
  •       20.2. Targeted Cancerous Stem Cells (CSCs)
  •          20.2.1. Global target CSCs market, 2018 - 2030 (USD Million)
  •          20.2.2. Global target CSCs market, by anti-cancer stem cell therapeutics
  •          20.2.3. Pathway inhibitors
  •                20.2.3.1. Global pathway inhibitors market, 2018 - 2030 (USD Million)
  •          20.2.4. Wnt signaling pathway
  •          20.2.5. Hedgehog (HH) signaling pathway
  •          20.2.6. Notch signaling pathway
  •          20.2.7. Others
  •       20.3. Surface marker-based
  •          20.3.1. Global surface marker-based market, 2018 - 2030 (USD Million)
  •       20.4. Immuno-evasion & targeting tumor microenvironment
  •          20.4.1. Global immuno-evasion & targeting tumor microenvironment market, 2018 - 2030 (USD Million)
  •       20.5. Nanoparticle-based therapies
  •          20.5.1. Global nanoparticle-based therapies market, 2018 - 2030 (USD Million)
  •       20.6. Others
  •          20.6.1. Global others market, 2018 - 2030 (USD Million)
  •       20.7. Global target CSCs market, by products
  •          20.7.1. Cell culturing
  •                20.7.1.1. Global cell culturing market, 2018 - 2030 (USD Million)
  •          20.7.2. Cell separation
  •                20.7.2.1. Global cell separation market, 2018 - 2030 (USD Million)
  •          20.7.3. Cell analysis
  •                20.7.3.1. Global cell analysis market, 2018 - 2030 (USD Million)
  •          20.7.4. Molecular analysis
  •                20.7.4.1. Global molecular analysis market, 2018 - 2030 (USD Million)
  •          20.7.5. Others
  •                20.7.5.1. Global others market, 2018 - 2030 (USD Million)
  •       20.8. Stem Cell-based Cancer Therapy
  •          20.8.1. Global Stem Cell-based Cancer Therapy market, 2018 - 2030 (USD Million)
  •       20.9. Autologous stem cell transplant
  •          20.9.1. Global autologous stem cell transplant market, 2018 - 2030 (USD Million)
  •       20.10. Allogeneic stem cell transplant
  •          20.10.1. Global allogeneic stem cell transplant market, 2018 - 2030 (USD Million)

Chapter 21. Cancer Stem Cells Market: Cancer Forms Estimates & Trend Analysis

  •       21.1. Global Cancer stem cells market: Cancer Forms Movement Analysis
  •       21.2. Breast Cancer
  •          21.2.1. Global breast cancer market, 2018 - 2030 (USD Million)
  •       21.3. Blood Cancer
  •          21.3.1. Global blood cancer market, 2018 - 2030 (USD Million)
  •       21.4. Lung Cancer
  •          21.4.1. Global lung cancer market, 2018 - 2030 (USD Million)
  •       21.5. Brain Cancer
  •          21.5.1. Global brain cancer market, 2018 - 2030 (USD Million)
  •       21.6. Colorectal Cancer
  •          21.6.1. Global colorectal cancer market, 2018 - 2030 (USD Million)
  •       21.7. Pancreas Cancer
  •          21.7.1. Global pancreas cancer market, 2018 - 2030 (USD Million)
  •       21.8. Bladder Cancer
  •          21.8.1. Global bladder cancer market, 2018 - 2030 (USD Million)
  •       21.9. Liver Cancer
  •          21.9.1. Global liver cancer market, 2018 - 2030 (USD Million)
  •       21.10. Others
  •          21.10.1. Global others market, 2018 - 2030 (USD Million)

Chapter 22. Stem Cells Industry - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  •       22.1. Stem Cells Market Share By Region, 2021 & 2030
  •       22.2. North America
  •          22.2.1. North America Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.2.2. U.S.
  •                22.2.2.1. U.S. Stem Cells Market, 2018 - 2030 (USD MILLION)
  •          22.2.3. Canada
  •                22.2.3.1. Canada Stem Cells Market, 2018 - 2030 (USD Million)
  •       22.3. Europe
  •          22.3.1. Europe Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.2. Germany
  •                22.3.2.1. Germany Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.3. UK
  •                22.3.3.1. UK Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.4. France
  •                22.3.4.1. France Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.5. Italy
  •                22.3.5.1. Italy Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.6. Spain
  •                22.3.6.1. Spain Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.7. Denmark
  •                22.3.7.1. Denmark Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.8. Sweden
  •                22.3.8.1. Sweden Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.3.9. Norway
  •                22.3.9.1. Norway Stem Cells Market, 2018 - 2030 (USD Million)
  •       22.4. Asia Pacific
  •          22.4.1. Asia Pacific Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.4.2. Japan
  •                22.4.2.1. Japan Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.4.3. China
  •                22.4.3.1. China Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.4.4. India
  •                22.4.4.1. India Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.4.5. South Korea
  •                22.4.5.1. South Korea Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.4.6. Australia
  •                22.4.6.1. Australia Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.4.7. Thailand
  •                22.4.7.1. Thailand Stem Cells Market, 2018 - 2030 (USD Million)
  •       22.5. Latin America
  •          22.5.1. Latin America Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.5.2. Brazil
  •                22.5.2.1. Brazil Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.5.3. Mexico
  •                22.5.3.1. Mexico Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.5.4. Argentina
  •                22.5.4.1. Argentina Stem Cells Market, 2018 - 2030 (USD Million)
  •       22.6. MEA
  •          22.6.1. MEA Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.6.2. South Africa
  •                22.6.2.1. South Africa Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.6.3. Saudi Arabia
  •                22.6.3.1. Saudi Arabia Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.6.4. UAE
  •                22.6.4.1. UAE Stem Cells Market, 2018 - 2030 (USD Million)
  •          22.6.5. Kuwait
  •                22.6.5.1. Kuwait Stem Cells Market, 2018 - 2030 (USD Million)

Chapter 23. Competitive Analysis

  •       23.1. Recent Developments & Impact Analysis, By Key Market Participants
  •          23.1.1. Ansoff Matrix
  •          23.1.2. Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
  •          23.1.3. Innovators
  •       23.2. Vendor Landscape
  •          23.2.1. List Of Key Distributors And Channel Partners
  •          23.2.2. Global Stem Cells Industry: Key Company Market Share Analysis, 2021
  •       23.3. Public Companies
  •          23.3.1. Company Market Position Analysis
  •          23.3.2. Competitive Dashboard Analysis
  •          23.3.3. Strategic Framework
  •       23.4. Private Companies
  •          23.4.1. List Of Key Emerging Companies/Technology Disruptors/Innovators
  •          23.4.2. Regional Network Map
  •       23.5. Company Profiles
  •          23.5.1. Advanced Cell Technology Inc.
  •                23.5.1.1. Company Overview
  •                23.5.1.2. Financial Performance
  •                23.5.1.3. Product Benchmarking
  •                23.5.1.4. Strategic Initiatives
  •          23.5.2. STEMCELL Technologies Inc.
  •                23.5.2.1. Company Overview
  •                23.5.2.2. Financial Performance
  •                23.5.2.3. Product Benchmarking
  •                23.5.2.4. Strategic Initiatives
  •          23.5.3. Cellular Engineering Technologies Inc.
  •                23.5.3.1. Company Overview
  •                23.5.3.2. Financial Performance
  •                23.5.3.3. Product Benchmarking
  •                23.5.3.4. Strategic Initiatives
  •          23.5.4. CellGenix GmbH
  •                23.5.4.1. Company Overview
  •                23.5.4.2. Financial Performance
  •                23.5.4.3. Product Benchmarking
  •                23.5.4.4. Strategic Initiatives
  •          23.5.5. PromoCell GmbH
  •                23.5.5.1. Company Overview
  •                23.5.5.2. Financial Performance
  •                23.5.5.3. Product Benchmarking
  •                23.5.5.4. Strategic Initiatives
  •          23.5.6. Kite Pharma
  •                23.5.6.1. Company Overview
  •                23.5.6.2. Financial Performance
  •                23.5.6.3. Product Benchmarking
  •                23.5.6.4. Strategic Initiatives
  •          23.5.7. Lonza
  •                23.5.7.1. Company Overview
  •                23.5.7.2. Financial Performance
  •                23.5.7.3. Product Benchmarking
  •                23.5.7.4. Strategic Initiatives
  •          23.5.8. Cellartis AB
  •                23.5.8.1. Company Overview
  •                23.5.8.2. Financial Performance
  •                23.5.8.3. Product Benchmarking
  •                23.5.8.4. Strategic Initiatives
  •          23.5.9. Angel Biotechnology
  •                23.5.9.1. Company Overview
  •                23.5.9.2. Financial Performance
  •                23.5.9.3. Product Benchmarking
  •                23.5.9.4. Strategic Initiatives
  •          23.5.10. Brainstorm Cell Therapeutics
  •                23.5.10.1. Company Overview
  •                23.5.10.2. Financial Performance
  •                23.5.10.3. Product Benchmarking
  •                23.5.10.4. Strategic Initiatives
  •          23.5.11. Celgene Corporation
  •                23.5.11.1. Company Overview
  •                23.5.11.2. Financial Performance
  •                23.5.11.3. Product Benchmarking
  •                23.5.11.4. Strategic Initiatives
  •          23.5.12. Osiris Therapeutics
  •                23.5.12.1. Company Overview
  •                23.5.12.2. Financial Performance
  •                23.5.12.3. Product Benchmarking
  •                23.5.12.4. Strategic Initiatives
  •          23.5.13. Genea Biocells
  •                23.5.13.1. Company Overview
  •                23.5.13.2. Financial Performance
  •                23.5.13.3. Product Benchmarking
  •                23.5.13.4. Strategic Initiatives
  •          23.5.14. Bioheart Inc.
  •                23.5.14.1. Company Overview
  •                23.5.14.2. Financial Performance
  •                23.5.14.3. Product Benchmarking
  •                23.5.14.4. Strategic Initiatives
  •          23.5.15. Waisman Biomanufacturing
  •                23.5.15.1. Company Overview
  •                23.5.15.2. Financial Performance
  •                23.5.15.3. Product Benchmarking
  •                23.5.15.4. Strategic Initiatives
  •          23.5.16. Tigenix
  •                23.5.16.1. Company Overview
  •                23.5.16.2. Financial Performance
  •                23.5.16.3. Product Benchmarking
  •                23.5.16.4. Strategic Initiatives
  •          23.5.17. Caladrius Biosciences
  •                23.5.17.1. Company Overview
  •                23.5.17.2. Financial Performance
  •                23.5.17.3. Product Benchmarking
  •                23.5.17.4. Strategic Initiatives
  •          23.5.18. Gamida Cell
  •                23.5.18.1. Company Overview
  •                23.5.18.2. Financial Performance
  •                23.5.18.3. Product Benchmarking
  •                23.5.18.4. Strategic Initiatives
  •          23.5.19. Thermo Fisher Scientific, Inc.
  •                23.5.19.1. Company Overview
  •                23.5.19.2. Financial Performance
  •                23.5.19.3. Product Benchmarking
  •                23.5.19.4. Strategic Initiatives
  •          23.5.20. AbbVie, Inc.
  •                23.5.20.1. Company Overview
  •                23.5.20.2. Financial Performance
  •                23.5.20.3. Product Benchmarking
  •                23.5.20.4. Strategic Initiatives
  •          23.5.21. Merck KGaA
  •                23.5.21.1. Company Overview
  •                23.5.21.2. Financial Performance
  •                23.5.21.3. Product Benchmarking
  •                23.5.21.4. Strategic Initiatives
  •          23.5.22. Bionomics
  •                23.5.22.1. Company Overview
  •                23.5.22.2. Financial Performance
  •                23.5.22.3. Product Benchmarking
  •                23.5.22.4. Strategic Initiatives
  •          23.5.23. Stemline Therapeutics, Inc
  •                23.5.23.1. Company Overview
  •                23.5.23.2. Financial Performance
  •                23.5.23.3. Product Benchmarking
  •                23.5.23.4. Strategic Initiatives
  •          23.5.24. Miltenyi Biotec
  •                23.5.24.1. Company Overview
  •                23.5.24.2. Financial Performance
  •                23.5.24.3. Product Benchmarking
  •                23.5.24.4. Strategic Initiatives
  •          23.5.25. PromoCell GmbH
  •                23.5.25.1. Company Overview
  •                23.5.25.2. Financial Performance
  •                23.5.25.3. Product Benchmarking
  •                23.5.25.4. Strategic Initiatives
  •          23.5.26. MacroGenics, Inc
  •                23.5.26.1. Company Overview
  •                23.5.26.2. Financial Performance
  •                23.5.26.3. Product Benchmarking
  •                23.5.26.4. Strategic Initiatives
  •          23.5.27. ONCOMED PHARMACEUTICALS INC
  •                23.5.27.1. Company Overview
  •                23.5.27.2. Financial Performance
  •                23.5.27.3. Product Benchmarking
  •                23.5.27.4. Strategic Initiatives
  •          23.5.28. Irvine Scientific
  •                23.5.28.1. Company Overview
  •                23.5.28.2. Financial Performance
  •                23.5.28.3. Product Benchmarking
  •                23.5.28.4. Strategic Initiatives
  •          23.5.29. Sino Biological Inc
  •                23.5.29.1. Company Overview
  •                23.5.29.2. Financial Performance
  •                23.5.29.3. Product Benchmarking
  •                23.5.29.4. Strategic Initiatives
  •          23.5.30. BIOTIME, INC
  •                23.5.30.1. Company Overview
  •                23.5.30.2. Financial Performance
  •                23.5.30.3. Product Benchmarking
  •                23.5.30.4. Strategic Initiatives
  •          23.5.31. Cell Cure Neurosciences LTD
  •                23.5.31.1. Company Overview
  •                23.5.31.2. Financial Performance
  •                23.5.31.3. Product Benchmarking
  •                23.5.31.4. Strategic Initiatives
  •          23.5.32. ESI BIO
  •                23.5.32.1. Company Overview
  •                23.5.32.2. Financial Performance
  •                23.5.32.3. Product Benchmarking
  •                23.5.32.4. Strategic Initiatives
  •          23.5.33. CELL APPLICATIONS, INC.
  •                23.5.33.1. Company Overview
  •                23.5.33.2. Financial Performance
  •                23.5.33.3. Product Benchmarking
  •                23.5.33.4. Strategic Initiatives
  •          23.5.34. CYAGEN BIOSCIENCES INC
  •                23.5.34.1. Company Overview
  •                23.5.34.2. Financial Performance
  •                23.5.34.3. Product Benchmarking
  •                23.5.34.4. Strategic Initiatives
  •          23.5.35. AXOL BIOSCIENCES LTD
  •                23.5.35.1. Company Overview
  •                23.5.35.2. Financial Performance
  •                23.5.35.3. Product Benchmarking
  •                23.5.35.4. Strategic Initiatives
  •          23.5.36. CYTORI THERAPEUTICS INC
  •                23.5.36.1. Company Overview
  •                23.5.36.2. Financial Performance
  •                23.5.36.3. Product Benchmarking
  •                23.5.36.4. Strategic Initiatives
  •          23.5.37. CELPROGEN INC
  •                23.5.37.1. Company Overview
  •                23.5.37.2. Financial Performance
  •                23.5.37.3. Product Benchmarking
  •                23.5.37.4. Strategic Initiatives
  •          23.5.38. BRAINSTORM CELL THERAPEUTICS INC
  •                23.5.38.1. Company Overview
  •                23.5.38.2. Financial Performance
  •                23.5.38.3. Product Benchmarking
  •                23.5.38.4. Strategic Initiatives
  •          23.5.39. STEMEDICA CELL TECHNOLOGIES INC.
  •                23.5.39.1. Company Overview
  •                23.5.39.2. Financial Performance
  •                23.5.39.3. Product Benchmarking
  •                23.5.39.4. Strategic Initiatives
  •          23.5.40. Merck Kgaa
  •                23.5.40.1. Company Overview
  •                23.5.40.2. Financial Performance
  •                23.5.40.3. Product Benchmarking
  •                23.5.40.4. Strategic Initiatives
  •          23.5.41. SMITH+NEPHEW
  •                23.5.41.1. Company Overview
  •                23.5.41.2. Financial Performance
  •                23.5.41.3. Product Benchmarking
  •                23.5.41.4. Strategic Initiatives
  •          23.5.42. SCIENCELL RESEARCH LABORATORIES
  •                23.5.42.1. Company Overview
  •                23.5.42.2. Financial Performance
  •                23.5.42.3. Product Benchmarking
  •                23.5.42.4. Strategic Initiatives
  •          23.5.43. AMERICAN TYPE CULTURE COLLECTION
  •                23.5.43.1. Company Overview
  •                23.5.43.2. Financial Performance
  •                23.5.43.3. Product Benchmarking
  •                23.5.43.4. Strategic Initiatives
  •          23.5.44. Axol Biosciences Ltd
  •                23.5.44.1. Company Overview
  •                23.5.44.2. Financial Performance
  •                23.5.44.3. Product Benchmarking
  •                23.5.44.4. Strategic Initiatives
  •          23.5.45. Evotec Se
  •                23.5.45.1. Company Overview
  •                23.5.45.2. Financial Performance
  •                23.5.45.3. Product Benchmarking
  •                23.5.45.4. Strategic Initiatives
  •          23.5.46. Hitachi Ltd
  •                23.5.46.1. Company Overview
  •                23.5.46.2. Financial Performance
  •                23.5.46.3. Product Benchmarking
  •                23.5.46.4. Strategic Initiatives
  •          23.5.47. Reprocells Inc
  •                23.5.47.1. Company Overview
  •                23.5.47.2. Financial Performance
  •                23.5.47.3. Product Benchmarking
  •                23.5.47.4. Strategic Initiatives
  •          23.5.48. Fate Therapeutics
  •                23.5.48.1. Company Overview
  •                23.5.48.2. Financial Performance
  •                23.5.48.3. Product Benchmarking
  •                23.5.48.4. Strategic Initiatives
  •          23.5.49. Stemcellsfactory Iii
  •                23.5.49.1. Company Overview
  •                23.5.49.2. Financial Performance
  •                23.5.49.3. Product Benchmarking
  •                23.5.49.4. Strategic Initiatives
  •          23.5.50. Applied Stemcells Inc
  •                23.5.50.1. Company Overview
  •                23.5.50.2. Financial Performance
  •                23.5.50.3. Product Benchmarking
  •                23.5.50.4. Strategic Initiatives
  •          23.5.51. Astellas Pharma Inc/ Ocata Therapeutics
  •                23.5.51.1. Company Overview
  •                23.5.51.2. Financial Performance
  •                23.5.51.3. Product Benchmarking
  •                23.5.51.4. Strategic Initiatives
  •          23.5.52. BIOTIME, INC. / Cell Cure Neurosciences LTD
  •                23.5.52.1. Company Overview
  •                23.5.52.2. Financial Performance
  •                23.5.52.3. Product Benchmarking
  •                23.5.52.4. Strategic Initiatives
  •          23.5.53. CellGenix GmbH
  •                23.5.53.1. Company Overview
  •                23.5.53.2. Financial Performance
  •                23.5.53.3. Product Benchmarking
  •                23.5.53.4. Strategic Initiatives
  •          23.5.54. ESI BIO
  •                23.5.54.1. Company Overview
  •                23.5.54.2. Financial Performance
  •                23.5.54.3. Product Benchmarking
  •                23.5.54.4. Strategic Initiatives
  •          23.5.55. Kite Pharma
  •                23.5.55.1. Company Overview
  •                23.5.55.2. Financial Performance
  •                23.5.55.3. Product Benchmarking
  •                23.5.55.4. Strategic Initiatives
  •          23.5.56. Cynata
  •                23.5.56.1. Company Overview
  •                23.5.56.2. Financial Performance
  •                23.5.56.3. Product Benchmarking
  •                23.5.56.4. Strategic Initiatives
  •          23.5.57. Sumanas, Inc
  •                23.5.57.1. Company Overview
  •                23.5.57.2. Financial Performance
  •                23.5.57.3. Product Benchmarking
  •                23.5.57.4. Strategic Initiatives
  •          23.5.58. LifeCell
  •                23.5.58.1. Company Overview
  •                23.5.58.2. Financial Performance
  •                23.5.58.3. Product Benchmarking
  •                23.5.58.4. Strategic Initiatives
  •          23.5.59. International Stem Cell Corporation
  •                23.5.59.1. Company Overview
  •                23.5.59.2. Financial Performance
  •                23.5.59.3. Product Benchmarking
  •                23.5.59.4. Strategic Initiatives
  •          23.5.60. Cordlife
  •                23.5.60.1. Company Overview
  •                23.5.60.2. Financial Performance
  •                23.5.60.3. Product Benchmarking
  •                23.5.60.4. Strategic Initiatives
  •          23.5.61. Genea BioCells
  •                23.5.61.1. Company Overview
  •                23.5.61.2. Financial Performance
  •                23.5.61.3. Product Benchmarking
  •                23.5.61.4. Strategic Initiatives
  •          23.5.62. Geron
  •                23.5.62.1. Company Overview
  •                23.5.62.2. Financial Performance
  •                23.5.62.3. Product Benchmarking
  •                23.5.62.4. Strategic Initiatives


What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.